Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

February 1, 2021

Study Completion Date

February 1, 2021

Conditions
Acute Promyelocytic Leukemia
Interventions
DRUG

Tretinoin and Arsenic Trioxide

See Detailed Description

Trial Locations (12)

10065

Memorial Sloan Kettering Cancer Center, New York

New York Presbyterian Hospital-Weill Medical College of Cornell University, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11725

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

20824

National Heart, Lung, and Blood Institute (NIH), Bethesda

44195

Cleveland Clinic, Cleveland

60208

Northwestern University, Evanston

90033

University of Southern California, Los Angeles

07920

Memorial Sloan Kettering at Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

Unknown

Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre

Princess Margaret Hospital/Ontario Cancer Institute, Toronto

All Listed Sponsors
collaborator

Northwestern University

OTHER

collaborator

New York Presbyterian Hospital

OTHER

collaborator

University of Southern California

OTHER

collaborator

Princess Margaret Hospital, Canada

OTHER

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT01404949 - Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy | Biotech Hunter | Biotech Hunter